Stockscreener 앱 받기
3.74
1.63%
0.06
전일 마감가:
$3.68
열려 있는:
$3.72
하루 거래량:
3.27M
Relative Volume:
1.61
시가총액:
$641.20M
수익:
$25.55M
순이익/손실:
$-341.97M
주가수익비율:
-1.3357
EPS:
-2.8
순현금흐름:
$-304.44M
1주 성능:
+6.86%
1개월 성능:
+14.72%
6개월 성능:
-22.89%
1년 성능:
-58.72%
1일 변동 폭
$3.60
$3.805
1주일 범위
$3.50
$3.87
52주 변동 폭
$1.775
$10.72
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
399 BINNEY STREET, CAMBRIDGE
RLAY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.74 | 630.92M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | Wells Fargo | Equal Weight |
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
What analysts say about Relay Therapeutics Inc. stockExceptional growth trajectory - PrintWeekIndia
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? - Yahoo Finance
Is Relay Therapeutics Inc. a good long term investmentFree Investment Community - PrintWeekIndia
When is the best time to buy Relay Therapeutics Inc. stockFree Consultation - jammulinksnews.com
Will Relay Therapeutics Inc. stock benefit from AI tech trendsFree Stock Index Interpretation - jammulinksnews.com
What drives Relay Therapeutics Inc. stock priceTremendous growth potential - PrintWeekIndia
Relay Therapeutics Inc. Stock Analysis and ForecastExceptional earning trajectories - jammulinksnews.com
Why Relay Therapeutics Inc. stock attracts strong analyst attentionLow Risk High Reward Picks - Newser
what makes relay therapeutics inc. stock price move sharplyTargeted 200 Percent Gain - Newser
Is Relay Therapeutics Inc. stock overhyped or has real potentialLong Term Secure Gain Stocks - Newser
Is Relay Therapeutics Inc. stock a good hedge against inflationFree Stock Market Insider Analysis - Newser
RLAY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - The Globe and Mail
How Relay Therapeutics Inc. stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
What makes Relay Therapeutics Inc. stock price move sharplyTrade Ready Signal - Newser
DekaBank Deutsche Girozentrale Raises Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Have Relay Therapeutics Insiders Been Selling Stock? - simplywall.st
Wealth Enhancement Advisory Services LLC Makes New $41,000 Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
AI drug discovery platform Market May See a Big Move | Major Giants - openPR.com
Relay Therapeutics CEO Patel sells $219k in shares By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? - TradingView
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT - Yahoo Finance
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology - PR Newswire
Unraveling Relay Therapeutics' 9.8% Spike: A Closer Look at the Anomaly - AInvest
In the Green: Relay Therapeutics Inc (RLAY) Closes at 3.06, Up/Down -6.42 from Previous Day - DWinneX
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
릴레이 테라퓨틱스 주식 (RLAY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Apr 30 '25 |
Sale |
3.00 |
10,739 |
32,217 |
390,081 |
| Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
355,376 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 29 '25 |
Sale |
3.23 |
3,558 |
11,492 |
368,319 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 28 '25 |
Sale |
3.17 |
2,690 |
8,527 |
371,877 |
| Bergstrom Donald A | President, R&D |
Apr 30 '25 |
Sale |
3.00 |
27,472 |
82,416 |
583,490 |
| Bergstrom Donald A | President, R&D |
Apr 28 '25 |
Sale |
3.17 |
4,090 |
12,965 |
610,962 |
| Adams Brian | Chief Legal Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
391,385 |
| Adams Brian | Chief Legal Officer |
Apr 28 '25 |
Sale |
3.17 |
1,644 |
5,211 |
404,328 |
0.97%
0.22%
자본화:
|
볼륨(24시간):